Supporting Information

Files in this Data Supplement:

Fig. 6. Tolerance in BALB/c hosts. (A) B10 skin was transplanted onto CBA (▲, n = 5, MST >100 days) or BALB/c (■, n = 12, MST = 69 days, P = 0.02 vs. ▲) mice, treated with the three mAbs as described, as well as onto untreated BALB/c mice (▼, n = 3, MST = 9 days, P < 0.0001 vs. ■). (B) BALB/c mice were transplanted with B10 skin at day 0, and were treated with nondepleting CD4, CD8, and CD154 mAbs, as described (see treatment table). One month following transplantation, at day 28, mice were treated with 4 × 10⁷ T cell-depleted B10 BM cells under the cover of the same mAb treatment (■), mAbs alone (▲), or BM alone (▼). Different mice were treated initially with the mAbs in the absence of a skin graft, followed by a further treatment with mAbs at day 28 (●), or BM together with mAbs and a B10 skin graft (u). (C) One hundred days following BM treatment, mice with surviving B10 skin grafts were transplanted with (B10´CBA)F₁ skin. (D) All mice were bled 120 days following BMT, to quantify the percentage of H2-D^b+ T cells in their peripheral blood by flow cytometry.